Kane Biotech Inc.

Fun video we received from AURENA Laboratories AB this week. Product is looking great (finished product in comments).

Join Marc Edwards, Kane’s President and CEO, as he reviews the highlights of another incredible quarter for Kane Biotech in culmination with the release of our outstanding Q3 financial numbers! 👉 Read the full press release: https://lnkd.in/eXYHaNpB #KaneBiotech #WoundHealing #revyve #KNE #KNBIF #Innovation #Dermatology #WoundCare #Innovation #Growth #FDAApproved #Healthcare #Biotech #Medical #WoundGel

More great news from Kane Biotech! 👏 Following a Letter of Intent signed by BioStem Technologies (OTC: BSEM), Kane is excited to announce BioStem as our new U.S. distribution partner for our revyve™ Antimicrobial Wound Gel! Our team is thrilled to partner with BioStem and is eager to continue our mission of bringing access to innovative wound care solutions and enhancing patient outcomes across the U.S. 👉 Read the full press release: https://lnkd.in/eHg2JGkV #KaneBio #revyve #WoundCare #FDAApproved #BioFilm #Health #WoundGel #USA #Medical #Innovation #WoundHealing #ChronicWounds #KNE #KNBIF

Congratulations to the Kane research team on the publication of their article: “Wound Gel Formulations Containing Poloxamer 407 and Polyhexanide Have In Vitro Antimicrobial and Antibiofilm Activity Against Wound-Associated Microbial Pathogens.” This achievement reflects our incredible team's expertise, dedication, and commitment to advancing knowledge in wound care. We’re proud to celebrate this milestone and look forward to the meaningful impact this work will have in the field! Read the full article: https://lnkd.in/ebaaz-Ws Jeyachchandran(Vije) Visvalingam, Ph.D. Suresh Regmi, PhD, P.Chem. Adetola A. Praveen Sharma Miloslav Sailer #KaneBio #WoundCare #revyve #FDAApproved #BioFilm #Health #WoundGel #Research #Medical #Biotech

We're pleased to announce that Kane Biotech's revyve™ Antimicrobial Wound Gel has been approved by Health Canada as a Class 2 Medical Device! 🙌 This is a huge achievement, and it wouldn't have been possible without the hard work of our dedicated team. We're excited to make revyve™ available to Canadians, bringing advanced wound care to those who need it most!  👉 Read the full article: https://lnkd.in/euDk4D6C #Biotech #KaneBio #revyve #HealthCanada #BioFilm #ChronicWounds #Wounds #WoundCare #WoundHealing #Health #Medical #MedicalDevice #Research #Patent #FDAapprovedProduct #WoundGel #KNE #KNBIF

It is an exciting time for Kane Biotech, as yesterday we announced an agreement to acquire FB Dermatology. Join our President and CEO, Marc Edwards, and Executive Chair, Dr. Robert Huizinga, as they discuss what this acquisition means for Kane and how it will expand our capabilities. 👉 Watch now: https://lnkd.in/gUBKucGr 👉 Read the full press release: https://lnkd.in/eYF2BpdT #KaneBiotech #Acquisition #FBDermatology #Dermatology #WoundCare #Innovation #Growth #KNE #KNBIF #FDAApproved #Health

Game-changing news from Kane Biotech! Proud to share we’re acquiring FB Dermatology to boost our leadership in advanced wound care and dermatology solutions worldwide.

🚀 Exciting News from Kane Biotech! TSXV : KNE - OTCQB : KNBIF We’re proud to announce a significant milestone in our journey. Kane Biotech has entered into an agreement to acquire FB Dermatology, a strategic move that strengthens our presence in the wound care and dermatology space and broadens our international reach. Why this is game-changing: Proven Technology: FB Dermatology's innovative Fluorescent Light Energy Technology (FLETECH) and products such as LumiHeal®, Kleresca®, and Lumixa® complement Kane Biotech’s portfolio, bringing advanced, patented solutions to the market. Commercial Synergies: This acquisition paves the way for the accelerated launch of our revyve™ Antimicrobial Wound Gel and DermaKB® products in Europe, Australia, and New Zealand, capitalizing on FB Dermatology’s strong local sales channels. Global Growth: Leveraging FB Dermatology’s established networks enhances our ability to introduce cutting-edge products, including the upcoming North American launch of LumiHeal® for surgical scar reduction. With this transaction, Kane Biotech positions itself as a leader in innovative, effective treatments that support the natural healing processes of the skin. This approach not only fuels our growth but also maximizes shareholder value by aligning with our financial strategies. Marc Edwards, President and CEO of Kane Biotech, said it best: “This acquisition sets the stage for rapid growth and positions Kane Biotech as a frontrunner in delivering advanced solutions in wound care and dermatology.” We’re thrilled for this new chapter and the positive impacts it promises for our industry, partners, and patients worldwide. #KaneBiotech #Acquisition #Dermatology #WoundCare #Innovation #Growth #KNE #KNBIF https://lnkd.in/egZpJdqJ

Thank you to the Winnipeg Free Press for featuring Kane Biotech’s commitment to making a positive impact through our donation of 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukrainian medical relief effort. (Please note, the article mistakenly mentions 20,000 ounces; the correct amount is 2,000 ounces.) 👉 Read the full article: https://lnkd.in/e4_iSaNk 👉 Read Kane’s full press release: https://lnkd.in/dicFStJC #StandWithUkraine #Ukraine #SupportUkraine #KaneBio #Revyve #FDAApprovedProduct #TSXVKNE #OTCQBKNBIF